

PRESS RELEASE
15 June 2021 10:20:00 CEST



New motion in Stockholm - Increased use of CoreTherm reduces costs and frees up resources.

Lars Bryntesson (S) writes in a new motion to the Regional Council of Region Stockholm on thermotherapy treatment (TUMT) in benign prostate enlargement.

A modern and developed form of TUMT is ProstaLunds CoreTherm®. The Social Democrats' Lars Bryntesson has motioned on thermotherapy treatment (TUMT) in benign prostate enlargement and wants efforts against benign prostate enlargement to be strengthened "so that more people can be subjected to a curative treatment." Below are some quotes from the motion:

"Unlike at TURP, the TUMT does not require operating theatres, surgical staff or a hospital bed."

"The more care that can be carried out without the need for operating theatres, surgical staff and hospital beds, the more we free up for other care"

"TURP is performed at our emergency hospitals and costs significantly more per treatment than TUMT, nearly three times as much. The compensation for TUMT has been slightly increased but with marginal effect."

"Increased use of TUMT would reduce other costs and free up resources in emergency hospitals."

"Curative treatment, whether TUMT or TURP, is cost-effective and, in addition to improving the quality of life for patients, is estimated to save SEK 150-200,000 per individual in future direct care costs where reducing catheter care will be the big gain."

Johan Wennerholm, Acting CEO ProstaLund comments: "CoreTherm is the worst enemy of healthcare debt and the regions, if the common resources are used smarter, can have more patients cured at a lower cost, just as Bryntesson says. Lars Bryntesson's motion also shows that more and more politicians, from more and more parties, realize that the queues must be actively worked away, thereby creating a better everyday life and future for all these men with prostate problems."

For further information, please contact:

Johan Wennerholm, Acting CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
15 June 2021 10:20:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

New motion in Stockholm - Increased use of CoreTherm reduces costs and frees up resources.